靶向治疗时代晚期甲状腺癌治疗进展
甲状腺癌发病率上升,晚期病例亦增加;分子研究揭示甲状腺癌高频携带可成药分子改变,包括实体瘤中最高的致癌驱动激酶融合频率。低分化和未分化甲状腺癌由高分化滤泡来源癌获得额外突变演化而来,驱动基因组改变的识别可预测肿瘤表型并指导治疗,推动了基因特异性系统治疗的显著进展。
要点
- 甲状腺癌高频携带可成药分子改变,驱动激酶融合频率居实体瘤之首。
- 低分化与未分化甲状腺癌由高分化滤泡来源癌获得额外突变演化而来。
- 识别驱动基因组改变可预测肿瘤表型并指导靶向治疗选择。
核心结论
- 对甲状腺癌致癌分子基础的深入理解推动了基因特异性系统治疗的显著进展。
研究设计与样本
- 本文为综述,聚焦侵袭性滤泡来源甲状腺癌与甲状腺髓样癌的分子特征及靶向治疗进展。
主要发现
- 甲状腺癌高频携带潜在可成药分子改变,包括全部实体瘤中频率最高的致癌驱动激酶融合。
- 低分化和未分化甲状腺癌分析证实,这些肿瘤由高分化滤泡来源甲状腺癌通过获得额外突变发展而来。
- 甲状腺癌驱动基因组改变的识别不仅预测肿瘤表型,还可指导治疗策略。
临床怎么用
- 对侵袭性滤泡来源甲状腺癌和甲状腺髓样癌可基于驱动基因组改变选择基因特异性系统治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background: Thyroid cancer is a common malignancy whose detection has increased significantly in past decades. Most of the increased incidence is due to detection of early well-differentiated thyroid cancer, but the incidence of more advanced thyroid cancers has increased as well. Recent methodological advancements have allowed for a deep understanding of the molecular underpinnings of the various types of thyroid cancer. Summary: Thyroid cancers harbor a high frequency of potential druggable molecular alterations, including the highest frequency of oncogenic driver kinase fusions seen across all solid tumors. Analyses of poorly differentiated and anaplastic thyroid carcinoma confirmed that these tumors develop from more well-differentiated follicular-derived thyroid cancers through acquired additional mutations. The recognition of driver genomic alterations in thyroid cancers not only predicts tumor phenotype but also now can inform treatment approaches. Conclusions: Major progress in understanding the oncogenic molecular underpinnings across the array of thyroid cancers has led to considerable gains in gene-specific systemic therapies for many cancers. This article focuses on the molecular characteristics of aggressive follicular-derived thyroid cancers and medullary thyroid cancer and highlights advancements in treating thyroid cancer in the era of targeted therapy.
引用
- Lubitz CC, Sadow PM, Daniels GH, et al. Progress in Treating Advanced Thyroid Cancers in the Era of Targeted Therapy. Thyroid. 2021. PMID: 33860688. doi:10.1089/thy.2020.0962
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。